HKSE:2269

WuXi Biologics (Cayman) Inc. · HKSE · Healthcare · HKD · FY for 2025

Figures on this page computed 2026-11-08 12:47 UTC

Last close

n/aHKD

Market data

34.9xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed
- Computed from the filing for 2025
12.8%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
22.5%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
12.8%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
0.07Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
HKD
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
HKD
- computed

Price is the furthest below its sector's middle: 0.25 against 0.36 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

2.23x

2.12x

-4.11x

0.89x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales2.23x
Its own average over 10 years, 9.78B.
Profit2.12x
Its own average over 10 years, 2.32B.
Free cash flow-4.11x
Its own average over 10 years, -680.8M.
Debt0.89x
Its own average over 8 years, 3.50B.
Pricen/a
Its own average over 0 years. Market data

Free cash flow is furthest from its own average, at -4.11 times.

Sales is 2.23 times its own 10-year average; Profit is 2.12 times its own 10-year average; Free cash flow is -4.11 times its own 10-year average; Debt is 0.89 times its own 8-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average2.23
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Profit against its own 10-year average2.12
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Free cash flow against its own 10-year average-4.11
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Debt against its own 8-year average0.89
Source
computed
Statement
income
Fiscal year
2025
Reported in
CNY
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
HKD